Primary hyperparathyroidism

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages 781-790

  Bilezikian, John ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATASE; PHOSPHORUS; RALOXIFENE;

ALBUMIN BLOOD LEVEL; BONE BIOPSY; BONE DENSITY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; COGNITION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIFFERENTIAL DIAGNOSIS; ECTOPIC HORMONE PRODUCTION; ESTROGEN DEFICIENCY; FRACTURE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERTENSION; HYPOCALCIURIA; HYPOPHOSPHATEMIA; KIDNEY CALCIFICATION; KIDNEY FAILURE; KIDNEY FUNCTION; MORPHOMETRICS; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PATIENT MONITORING; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM; TERTIARY HYPERPARATHYROIDISM; TREATMENT INDICATION; UREA NITROGEN BLOOD LEVEL; VITAMIN D DEFICIENCY; X RAY SPECTROMETRY;

EID: 84867392428     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12166.RA     Document Type: Review

References (87)

1. Souberbielle JC, Maury E, Friedlander G, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J Steroid Biochem Mol Biol. 2010;121:199-203.
2. Wallace LB, Parikh RT, Ross LV, et al. The phenotype of primary hyperparathyroidism with normal parathyroid hormone levels: How low can parathyroid hormone go? Surgery. 2011;150:1102-1112.
3. Fuleihan GE, Brown EM, Heath HH III. Familial benign hypocalciuric hypercalcemia and neonatal primary hyper-parathyroidism. In: Bilezikian JP, Raisz LG, Martin TJ, eds. Principles of Bone Biology. 3rd ed. San Diego, CA: Academic Press; 2008:1327-1345.
4. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab. 2007;3:122-133.
5. Arnold A, Brown MF, Ureña P, Gaz RD, Sarfati E, Drüeke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperpla-sia. J Clin Invest. 1995;95:2047-2053.
6. Arnold A. Molecular basis of primary hyperparathyroid-ism. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids. 2nd ed. San Diego, CA: Academic Press; 2001:331-347.
7. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: A "forme fruste" of an old disease. J Clin Endocrinol Metab. 2003;88:5348-5352.
8. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92: 3001-3005.
9. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: Evidence for a generalized target-Tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88:4641-4648.
10. Bilezikian JP Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2010; 54:106-109.
11. Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the manage-ment of asymptomatic primary hyperparathyroidism: Sum-mary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335-339.
12. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroid-ism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001-3005.
13. Cusano NE, Maalouf NM, Dworakowski E, Zhang C, Cremers SC, Bilezikian JP. Epidemiology and natural his-Tory of normocalcemic primary hyperparathyroidism and normocalcemic hypoparathyroidism. J Bone Miner Res. In press.
14. Heath H 3rd, Hodgson SF, Kennedy MA. Primary hyper-parathyroidism. Incidence, morbidity, and potential eco-nomic impact in a community. N Engl J Med. 1980;302: 189-193.
15. Lundgren E. Primary hyperparathyroidism of postmeno-pausal females. Prospective case-control analysis on preva-lence, clinical characteristics and treatment. Ups J Med Sci. 1999;104:87-130.
16. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O'Fallon WM, Melton LJ 3rd. The rise and fall of pri-mary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997; 126:433-440.
17. Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA. 1990;264:581-584.
18. Thakker RV, Newey PJ, Walls GV, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab. 2012 [Epub ahead of print].
19. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal dis-ease in primary hyperparathyroidism. J Bone Miner Res. 1989;4:283-291.
20. Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K. Parathyroidectomy improves bone geometry and micro-Architecture in female patients with primary hyperpara-Thyroidism: A one-year prospective controlled study using high-resolution peripheral quantitative computed tomogra-phy. J Bone Miner Res. 2012;27:1150-1158.
21. Bilezikian JP. Clinical use of parathyroid hormone in osteo-porosis. In: Adler RA, ed. Osteoporosis-Pathophysiology and Clinical Management. 2nd ed. Totowa, NJ: Humana Press; 2010:511-526.
22. Silva BC, Bilezikian JP. New approaches to the treatment of osteoporosis. Ann Rev Med. 2011;62:307-322.
23. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteo-penia: A new indication for surgery in primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 1996;81:4007-4012.
24. Dempster DW, Parisien M, Silverberg SJ, et al. On the mechanism of cancellous bone preservation in postmeno-pausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999;84:1562-1566.
25. Dempster DW, Müller R, Zhou H, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41:19-24.
26. Dauphine RT, Riggs BL, Scholz DA. Back pain and ver-Tebral crush fractures: An unrecognized mode of presenta-Tion for primary hyperparathyroidism. Ann Intern Med. 1975;83:365-367.
27. Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: A population-based study. J Bone Min Res. 1999;14:1700-1707.
28. Wilson RJ, Rao S, Ellis B, Kleerekoper M, Parfitt AM. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med. 1988;109:959-962.
29. Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Heath H 3rd. Risk of age-related fractures in patients with primary hyper-parathyroidism. Arch Intern Med. 1992;152:2269-2273.
30. Vignali E, Viccica G, Diacinti D, et al. Morphometic ver-Tebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94: 2306-2312.
31. Seeman E. Bone quality: The material and structural basis of bone strength. J Bone Miner Res. 2008;26:1-8.
32. Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res. 2002;17:1741-1743.
33. Bilezikian JP. Bone strength in primary hyperparathyroid-ism. Osteoporosis Int. 2003;14(Suppl 5):S113-S117.
34. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathy-roidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255.
35. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natu-ral history of primary hyperparathyroidism with or with-out parathyroid wurgery after 15 years. J Clin Endocrinol Metab. 2008;93:3462-3470.
36. Tamura Y, Araki A, Chiba Y, Mori S, Hosoi T, Horiuchi T. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: A 5-year follow-up study. J Bone Miner Metab. 2007;25:226-231.
37. Sitges-Serra A, Garcia L, Prieto R, Perla MJ, Nogués X, Sancho JJ. Effect of parathyroidectomy for primary hyper-parathyroidism on bone mineral density in postmenopausal women. Br J Surg. 2010;97;1013-1019.
38. Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal effects of interventions in mild primary hyper-parathyroidism: A meta-Analysis. J Clin Endocrinol Metab. 2010;95:1653-1662.
39. Vestergaard P, Mosekilde L. Parathyroid surgery is asso-ciated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: A controlled cohort study. J Intern Med. 2004;255:108-114.
40. Silverberg SJ, Bilezikian JP. Primary hyperparathyroid-ism. In: DeGroot LJ, Jameson JL, eds; Potts JT, section ed. Endocrinology. 6th ed. Philadelphia, PA: Elsevier-Saunders; 2010:1176-1197.
41. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyper-parathyroidism: Proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:351-365.
42. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kid-ney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.
43. Kidney Disease: Improving Global Outcomes (KIDIGO) CKD-MBD Work Group. KDIGO clinical practice guide-line for the diagnosis, evaluation, prevention, and treat-ment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-S130.
44. Walker MD, Dempster DW, McMahon DJ, et al. Effect of renal function on skeletal health in primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 2012;97:1501-1507.
45. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuromuscular disease in primary hyperparathyroidism. Ann Inter Med. 1974;80:182-194.
46. Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic pri-mary hyperparathyroidism. Am J Med. 1989;87:553-557.
47. Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med. 1994;96:101-106.
48. Roman S, Sosa JA. Psychiatric and cognitive aspects of primary hyperparathyroidism. Curr Opin Oncol. 2007; 19:1-5.
49. Pasieka JL, Parsons LL, Demeure MJ, et al. Patient-based surgical outcome tool demonstrating alleviation of symp-Toms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 2002;26:942-949.
50. Quiros RM, Alef MJ, Wilhelm SM, Djuricin G, Loviscek K, Prinz RA. Health-related quality of life in hyperpara-Thyroidism measurably improves after parathyroidectomy. Surgery. 2003;134:675-681.
51. Rao DS, Philips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery vs no sur-gery in patients with mild PHPT. J Clin Endocrinol Metab. 2004;89:5415-5422.
52. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: A prospec-Tive, randomized trial. J Clin Endocrinol Metab. 2007;92: 1687-1692.
53. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperpara-Thyroidism: A prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92:3114-3121.
54. Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroid-ism: A prospective study. J Clin Endocrinol Metab. 2009; 94:1951-1958.
55. Walker MD, Silverberg SJ. Parathyroidectomy in asymp-Tomatic primary hyperparathyroidism: Improves "bones" but not "psychic moans". J Clin Endocrnol Metab. 2007; 92:1613-1615.
56. Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: A tale of two cities-New York and Beijing. Int J Fertil Womens Med. 2000;45: 158-165.
57. Mithal A, Bandeira F, Meng X, et al. Primary hyperpara-Thyroidism in India, Brazil and China. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids. 2nd ed. San Diego, CA: Academic Press; 2001: 375-386.
58. Lumb GA, Stanbury SW. Parathyroid function in human vitamin D deficiency in primary hyperparathyroidism. Am J Med. 1974;54:833-839.
59. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with pri-mary hyperparathyroidism. Am J Med. 1999;107:561-567.
60. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D deficiency. J Clin Endocrinol Metab. 2005;90:2122-2126.
61. Stein EM, Dempster DW, Udesky J, et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone. 2011;48:557-561.
62. Ringe JD. Reversible hypertension in primary hyperpara-Thyroidism-pre- and posteroperative blood pressure in 75 cases. Klin Wochenschr. 1984;62:465-469.
63. Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL. Cardiac function in mild primary hyper-parathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol. 2010;163:461-467.
64. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 2005;90;3326-3330.
65. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 2010;95:2172-2179.
66. Walker MD, Fleischer J, Rundek T, McMahon DJ, Homma S, Sacco R, Silverberg SJ. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:3849-3856.
67. Khan AA, Bilezikian JP, Potts JT Jr; Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and man-Agement of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab. 2009;94:333-334.
68. Yu N, Leese GP, Smith D, Donnan PT. The natural his-Tory of treated and untreated primary hyperparathyroidism: The parathyroid epidemiology and audit research study. QJM. 2011;104:513-521.
69. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroid-ism: Proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:366-372.
70. Udelsman R, Lin Z, Donovan P. The superiority of mini-mally invasive parathyroidectomy based on 1650 consecu-Tive patients with primary hyperparathyroidism. Ann Surg. 2011:253;585-591.
71. Augustine MM, Bravo PE, Zeiger MA. Surgical treat-ment of primary hyperparathyroidism. Endocr Pract. 2011; 17(Suppl 1)75-82.
72. Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imag-ing: Technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am J Roentgenol. 2007; 188:1706-1715.
73. Lewiecki EM. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. J Clin Densitom. 2010;12:324-334.
74. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turn-over in postmenopausal women with primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 2003;88:1174-1178.
75. Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res. 2001;16:189-190.
76. Khan AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: A double-blind, random-ized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325.
77. Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA. Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract. 2009;15:705-713.
78. Marcocci C, Cianferotti L, Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism in men. In: Orwoll E, Bilezikian JP, Vanderscheuren D, eds, Osteoporosis in Men. San Diego, CA: Elsevier; 2010: 465-478.
79. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581-587.
80. Locatelli F, Pontoriero G, Limardo M, Tentori F. Cinacalcet hydrochloride: Calcimimetic for the treatment of hyperparathyroidism. Expert Rev Endocrinol Metab. 2006; 1:167-179.
81. Messa P, Alfieri C, Brezzi B. Clinical utilization of cina-calcet in hypercalcemic conditions. Expert Opin Drug Metab Toxicol. 2011;7:517-528.
82. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet nor-malizes serum calcium in subjects with primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 2003;88:5644-5649.
83. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-Term normocalcemia in patients with primary hyperpara-Thyroidism. J Clin Endocrinol Metab. 2005;90:135-141.
84. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94:4860-4867.
85. Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCl reduces hypercalcemia in primary hyper-parathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011;96:E9-E18.
86. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2766-2772.
87. Marcocci C, Cetani F. Clinical Practice: Primary hyper-parathyroidism. N Eng J Med. 2011;365:2389-2397.